A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer

@article{Willeke2007API,
  title={A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer},
  author={Frank Willeke and Karoline Horisberger and Uta Kraus-Tiefenbacher and Frederick Wenz and Armin Leitner and Andreas Hochhaus and Rainer Grobholz and A. C. M. Willer and Georg F. B. A. Kaehler and Stefan Post and Ralf-Dieter Hofheinz},
  journal={British Journal of Cancer},
  year={2007},
  volume={96},
  pages={912 - 917}
}
We sought to evaluate the efficacy and safety data of a combination regimen using weekly irinotecan in combination with capecitabine and concurrent radiotherapy (CapIri-RT) as neoadjuvant treatment in rectal cancer in a phase-II trial. Patients with rectal cancer clinical stages T3/4 Nx or N+ were recruited to receive irinotecan (50 mg m−2 weekly) and capecitabine (500 mg m−2 bid days 1–38) with a concurrent RT dose of 50.4 Gy. Surgery was scheduled 4–6 weeks after the completion of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 25 references

Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer

  • R-D Hofheinz, B von Gerstenberg-Helldorf, +7 authors F Willeke
  • J Clin Oncol
  • 2005
Highly Influential
6 Excerpts

R, for the NCRI colorectal cancer study group and CRO 7 participants

  • D Sebag-Montefiore, R Steele, +7 authors Stephens
  • Preliminary results of the MRC CR07
  • 2006
Highly Influential
4 Excerpts

Continuous infusion of 5-FU and weekly irinotecan with concurrent radiotherapy as neoadjuvant treatment for locally advanced or recurrent rectal cancer

  • G Klautke, R Kirchner, U Hopt, F Prall, T Foitzik, R Fietkau
  • Br J Cancer 92:
  • 2005
Highly Influential
3 Excerpts

A phase III trial comparing FULV to FULV+oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07

  • N Wolmark, HS Wieand, JP Kuebler, L Colangelo, RE Smith
  • Proc Am Soc Clin Oncol
  • 2005
1 Excerpt

Similar Papers

Loading similar papers…